Swipe om te navigeren naar een ander artikel
The main purpose of this meta-analysis was to evaluate the impact of beta-thalassemia major (BTM) on the health-related quality of life as assessed by the medical outcomes short-form-36 questionnaire (SF-36).
A systematic literature search was performed on Cochrane library, Web of Science, Scopus, Science Direct, ProQues, Medline/PubMed, Scholar Google until March 17, 2017 to obtain eligible studies. A fixed effect model was applied to summarize the scores of each domain. The radar chart was used to compare the scores of BTM patients with other health conditions. Spearman’s correlation analysis and meta-regression were used to explore the related factors.
26 studies were included in this study, which were all reliable to summarize the scores of the SF36. Pooled mean scores of the physical health domains ranged from 52.74 to 74.5, with the GH and PF domains being the lowest and the highest, respectively. Further, the pooled mean scores of the mental health domains varied between 59.6 and 71.11, with the (MH-VT) and SF domains being the maximum and the minimum, respectively. Patients with BTM had a substantially compromised HRQoL in comparison with the general population.
BTM could adversely affect the HRQoL of patients. Measuring HRQoL should be considered as an essential part of the overall assessment of health status of BTM patients, which would provide valuable clues for improving the management of disease and making decisions on the treatment.
Log in om toegang te krijgen
Met onderstaand(e) abonnement(en) heeft u direct toegang:
Caocci, G., La Nasa, G., D’Aloja, E., Vacca, A., Piras, E., Pintor, M., et al. (2011). Ethical issues of unrelated hematopoietic stem cell transplantation in adult thalassemia patients. BMC Medical Ethics, 12(1):4.
Kuesap, J., Chaijaroenkul, W., Rungsihirunrat, K., Pongjantharasatien, K., & Na-Bangchang, K. (2015). Coexistence of malaria and thalassemia in malaria endemic areas of Thailand. The Korean Journal of Parasitology, 53(3), 265.
Weatherall, D. (1997). Thalassaemia and malaria, revisited. Annals of Tropical Medicine & Parasitology, 91(7), 885–890.
Vichinsky, E. P., MacKlin, E. A., Waye, J. S., Lorey, F., & Olivieri, N. F. (2005). Changes in the epidemiology of thalassemia in North America: a new minority disease. Pediatrics, 116(6), e818–e825.
Hassanzadeh, J., Mirahmadizadeh, A., Karimi, M., & Rezaeian, S. (2017). Delay in diagnosis of hemoglobulinopathies (thalassemia, sickle cell anemia): A need for management of thalassemia programs. Iranian Journal of Pediatrics, 27(2), e6740.
Safizadeh, H., Farahmandinia, Z., Nejad, S. S., Pourdamghan, N., & Araste, M. (2012). Quality of life in patients with thalassemia major and intermedia in kerman-iran (I.R.). Mediterranean Journal of Hematology & Infectious Diseases, 4(1), e2012058.
Waheed, F. (2015). Thalassaemia prevention in Maldives: Effectiveness of primary, secondary and tertiary prevention interventions. Crawley: The University of Western Australia.
Tari, K., Valizadeh Ardalan, P., Abbaszadehdibavar, M., Atashi, A., Jalili, A., & Gheidishahran, M. (2018). Thalassemia an update: Molecular basis, clinical features and treatment. International Journal of Biomedicine and Public Health, 1(1), 48–58.
Donovan, A., Lima, C. A., Pinkus, J. L., Pinkus, G. S., Zon, L. I., Robine, S., et al. (2005). The iron exporter ferroportin/Slc40a1 is essential for iron homeostasis. Cell Metabolism, 1(3), 191–200.
Rachmilewitz, E. A., & Giardina, P. J. (2011). How I treat thalassemia. Blood, 118(13), 3479–3488.
Nisbet-Brown, E., Olivieri, N. F., Giardina, P. J., Grady, R. W., Neufeld, E. J., Séchaud, R., et al. (2003). Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: A randomised, double-blind, placebo-controlled, dose-escalation trial. The Lancet, 361(9369), 1597–1602.
Porter, J., Bowden, D. K., Economou, M., Troncy, J., Ganser, A., Habr, D., et al. (2012). Health-related quality of life, treatment satisfaction, adherence and persistence in β-thalassemia and myelodysplastic syndrome patients with iron overload receiving deferasirox: Results from the EPIC clinical trial. Anemia. https://doi.org/10.1155/2012/297641.
Abdul-Zahra, H. A. I., Hassan, M. K., & Ahmed, B. A. A. H. (2016). Health-related quality of life in children and adolescents with β-thalassemia major on different iron chelators in Basra, Iraq. Journal of Pediatric Hematology/Oncology, 38(7), 503–511.
Telfer, P., Constantinidou, G., Andreou, P., Christou, S., Modell, B., & Angastiniotis, M. (2005). Quality of life in thalassemia. Annals of the New York Academy of Sciences, 1054(1), 273–282.
Klaassen, R., Alibhai, S., & Moreau, K. (2013). Introducing the TranQol: A new disease-specific quality of life measure for children and adults with thalassemia major. Journal of Blood Disorders and Transfusion. https://doi.org/10.4172/2155-9864.1000150.
Senol, S. P., Tiftik, E. N., Unal, S., Akdeniz, A., Tasdelen, B., & Tunctan, B. (2016). Quality of life, clinical effectiveness, and satisfaction in patients with beta thalassemia major and sickle cell anemia receiving deferasirox chelation therapy. Journal of Basic & Clinical Pharmacy, 7(2), 49–59.
Abetz, L., Baladi, J.-F., Jones, P., & Rofail, D. (2006). The impact of iron overload and its treatment on quality of life: Results from a literature review. Health and Quality of Life Outcomes, 4(1), 73.
Hachim, I. Y., Al Nuaimi, Y. E., Abd El Baky, A., Al Hashmi, F., Rahman, A., Mazroei, S., et al. (2014). Quality of life in patients suffering from thalassaemia in Ras Al Khaimah, United Arab Emirates. Hamdan Medical Journal, 212, 1–7.
Ware, J. E. Jr., & Sherbourne, C. D. (1992). The MOS 36-item short-form health survey (SF-36): I. Conceptual framework and item selection. Medical Care, 30, 473–483.
Azarkeivan, A., Hajibeigi, B., Alavian, S. M., Lankarani, M. M., & Assarf, S. (2009). Associates of poor physical and mental health-related quality of life in beta thalassemia-major/intermedia. Journal of Research in Medical Sciences, 14(6), 349–355.
Dahlui, M., Hishamshah, M. I., Rahman, A. J. A., & Aljunid, S. M. (2009). Quality of life in transfusion-dependent thalassaemia patients on desferrioxamine treatment. Singapore Medical Journal, 50(8), 794–799.
Hajibeigi, B., Azarkeyvan, A., Alavian, S. M., Lankarani, M. M., & Assari, S. (2009). Anxiety and depression affects life and sleep quality in adults with beta-thalassemia. Indian Journal of Hematology and Blood Transfusion, 25(2), 59–65.
Vandenbroucke, J. P., von Elm, E., Altman, D. G., Gotzsche, P. C., Mulrow, C. D., Pocock, S. J., et al. (2007). Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and elaboration. Annals of Internal Medicine, 147(8), W163–W194.
Higgins, J. P., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003). Measuring inconsistency in meta-analyses. BMJ, 327(7414), 557–560.
Harris, R., Bradburn, M., Deeks, J., Harbord, R., Altman, D., & Steichen, T. (2010). Module for fixed and random effects meta-analysis. Boston College: Statistical software Components. Department of Economics.
Jenkinson, C., Coulter, A., & Wright, L. (1993). Short form 36 (SF36) health survey questionnaire: Normative data for adults of working age. BMJ: British Medical Journal, 306(6890), 1437–1440.
Ribu, L., Hanestad, B. R., Moum, T., Birkeland, K., & Rustoen, T. (2007). A comparison of the health-related quality of life in patients with diabetic foot ulcers, with a diabetes group and a nondiabetes group from the general population. Quality of Life Research, 16(2), 179–189.
Clarke, P. M., Simon, J., Cull, C. A., & Holman, R. R. (2006). Assessing the impact of visual acuity on quality of life in individuals with type 2 diabetes using the short form-36. Diabetes Care, 29(7), 1506–1511.
Yang, X., Fan, D., Xia, Q., Wang, M., Zhang, X., Li, X., et al. (2016). The health-related quality of life of ankylosing spondylitis patients assessed by SF-36: A systematic review and meta-analysis. Quality of Life Research, 25(11), 2711–2723.
Baraz, S., Miladinia, M., & Mosavinouri, E. (2016). A comparison of quality of life between adolescences with beta thalassemia major and their healthy peers. International Journal of Pediatrics, 4(1), 1195–1204.
Zahmatkeshan, N., Mobasser, N., & Zamanzadeh, V. (2016). Quality of life in thalassemia major patients in an Iranian district. Global Journal of Health Science, 9(5), 266.
Zarea, K., Baraz Pordanjani, S., Pedram, M., & Pakbaz, Z. (2010). Quality of life in children with thalassemia who referred to Thalassemia Center of Shafa Hospital. Jundishapour University of Medical Sciences Journal, 8(4), 455–462.
Emadi, D., Rasooli, L., & Mohammadi Farsani, S. (2016). Quality of life among patients with beta-thalassemia major in Shahrekord city, Iran. International Journal of Epidemiologic Research, 3(4), 324–328.
Adib-Hajbaghery, M., & Ahmadi, M. (2015). Health related quality of life, depression, anxiety and stress in patients with beta-thalassemia major. Iranian Journal of Pediatric Hematology & Oncology, 5(4), 193–205.
Amani, F., Fathi, A., Valizadeh, M., Farzaneh, E., & Fattahzadeh-Ardalani, G. (2015). Quality of life among Ardabil patients with beta-thalassemia major. International Journal of Research in Medical Sciences, 3(11), 3308–3312.
Javanbakht, M., Keshtkaran, A., Shabaninejad, H., Karami, H., Zakerinia, M., & Delavari, S. (2015). Comparison of blood transfusion plus chelation therapy and bone marrow transplantation in patients with beta-thalassemia: Application of SF-36, EQ-5D, and visual analogue scale measures. International Journal of Health Policy and Management, 4(11), 733–740.
Khairkhah, F., Mahmoodi Nesheli, H., Khodabakhsh, E., & Hosseini, S. R. (2015). Evaluation of mental health and quality of life among β-thalassemia major patients. Caspian Journal of Pediatrics, 1(2), 54–59.
Mahmoud, M. A. M. Health related quality of life in Thalassemia patients treated by iron chelation therapy in the United arab Emirates 2015.
Vafaei M., Azad, M., Shiargar, P., & Kazemi Haki, B. (2015). Quality of life in patients with thalassemia major referred to Ardabil Buali Hospital in 2012-13. Medical Sciences Journal, 25(4), 305–310.
Amoudi, A. S., Balkhoyor, A. H., Abulaban, A. A., Azab, A. M., Radi, S. A., Ayoub, M. D., et al. (2014). Quality of life among adults with beta-thalassemia major in western Saudi Arabia. Saudi Medical Journal, 35(8), 882–885.
Klaassen, R. J., Barrowman, N., Merelles-Pulcini, M., Vichinsky, E. P., Sweeters, N., Kirby-Allen, M., et al. (2014). Validation and reliability of a disease-specific quality of life measure (the TranQol) in adults and children with thalassaemia major. British Journal of Haematology, 164(3), 431–437.
Yengil, E., Acipayam, C., Kokacya, M. H., Kurhan, F., Oktay, G., & Ozer, C. (2014). Anxiety, depression and quality of life in patients with beta thalassemia major and their caregivers. International Journal of Clinical and Experimental Medicine, 7(8), 2165–2172.
Gollo, G., Savioli, G., Balocco, M., Venturino, C., Boeri, E., Costantini, M., et al. (2013). Changes in the quality of life of people with thalassemia major between 2001 and 2009. Patient Preference and Adherence, 7, 231–236.
Haghpanah, S., Nasirabadi, S., Ghaffarpasand, F., Karami, R., Mahmood, M., Parand, S., et al. (2013). Quality of life among iranian patients with beta-thalassemia major using the SF-36 questionnaire. Sao Paulo Medical Journal, 131(3), 166–172.
Imani, E., Asadi Nooghabi, F., Hosseini Teshnizi, S., Yosefi, P., & Salari, F. (2013). Comparison quality of life in patients with thalassemia major based on participating in group activities, Bandar Abbas. Scientific Journal of Iran Blood Transfus Organ, 10(2), 198–206.
La Nasa, G., Caocci, G., Efficace, F., Dessi, C., Vacca, A., Piras, E., et al. (2013). Long-term health-related quality of life evaluated more than 20 years after hematopoietic stem cell transplantation for thalassemia. Blood, 122(13), 2262–2270.
Goulas, V., Kourakli-Symeonidis, A., & Camoutsis, C. (2012). Comparative effects of three iron chelation therapies on the quality of life of greek patients with homozygous transfusion-dependent Beta-thalassemia. Isrn Hematology Print, 2012, 139862.
Khani, H., Majdi, M. R., Azad Marzabadi, E., Montazeri, A., Ghorbani, A., & Ramezani, M. (2012). Quality of life of iranian β-thalassaemia major patients living on the southern coast of the caspian sea. Eastern Mediterranean Health Journal, 18(5), 539–545.
Musallam, K. M., Khoury, B., Abi-Habib, R., Bazzi, L., Succar, J., Halawi, R., et al. (2011). Health-related quality of life in adults with transfusion-independent thalassaemia intermedia compared to regularly transfused thalassaemia major: New insights. European Journal of Haematology, 87(1), 73–79.
Hadi, N., Karami, N., & Montazeri, A. (2009). Health-related quality of life in Major thalassemic patients. Payesh, 8(4), 387–393.
Messina, G., Colombo, E., Cassinerio, E., Ferri, F., Curti, R., Altamura, C., et al. (2008). Psychosocial aspects and psychiatric disorders in young adult with thalassemia major. Internal and Emergency Medicine, 3(4), 339–343.
Leavell, H. R. (1956). Applied preventive medicine (rheumatic fever and rheumatic heart disease). Annual Review of Medicine, 7(1), 489–498.
Caocci, G., Vacca, A., Piras, E., Serreli, V., Dessi, C., Marcias, M., et al. (2016). Return to normal life after hematopoietic stem cell transplantation for thalassemia: A study of patients transplanted from matched sibling donors. Bone Marrow Transplantation, 51(12), 1640.
Piga, A. G., Tartaglione, I., Gamberini, R., Voskaridou, E., Melpignano, A., Ricchi, P., et al. (2016). Luspatercept increases hemoglobin, decreases transfusion burden and improves iron overload in adults with beta-thalassemia. Blood, 128(22), 851.
Ware, J. E. (2000). Jr. SF-36 health survey update. Spine, 25(24), 3130–3139.
Bonakdaran, S., Khajeh-Dalouie, M., & Jalili-Shahri, J. (2010). Correlation between serum zinc level with impaired glucose tolerance and insulin resistance in major thalassemic patients. Iranian Journal of Endocrinology and Metabolism, 11(6), 667–672, 735.
Arian, M., Memarian, R., Vakilian, F., & Badiee, Z. (2013). Impact of an 8-week walking program on quality of life in patients with thalassemia major. Feyz Journal of Kashan University of Medical Sciences, 17(5), 463–470.
Pathare, A., Taher, A., & Daar, S. (2010). Deferasirox (Exjade®) significantly improves cardiac T2* in heavily iron-overloaded patients with β-thalassemia major. Annals of Hematology, 89(4), 405–409.
Taher, A., Al Jefri, A., Elalfy, M. S., Al Zir, K., Daar, S., Rofail, D., et al. (2010). Improved treatment satisfaction and convenience with deferasirox in iron-overloaded patients with β-thalassemia: results from the ESCALATOR trial. Acta Haematologica, 123(4), 220–225.
Borgna-Pignatti, C., Rugolotto, S., De Stefano, P., Zhao, H., Cappellini, M. D., Del Vecchio, G. C., et al. (2004). Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica, 89(10), 1187–1193.
Pepe, A., Meloni, A., Capra, M., Cianciulli, P., Prossomariti, L., Malaventura, C., et al. (2010). Deferasirox, deferiprone and desferrioxamine treatment in thalassemia major patients: Cardiac iron and function comparison determined by quantitative magnetic resonance imaging. Haematologica, 2009, 019042.
Ismail, A., Campbell, M. J., Ibrahim, H. M., & Jones, G. L. (2006). Health related quality of life in Malaysian children with thalassaemia. Health and Quality of Life Outcomes, 4(1), 39.
- Health-related quality of life (HRQoL) in beta-thalassemia major (β-TM) patients assessed by 36-item short form health survey (SF-36): a meta-analysis
- Springer International Publishing